Mediq (688079.SH): Optical semiconductor company plans to introduce strategic investor Fuzhe Shaoxin

Zhitong Finance App News, Mediq (688079.SH) announced that the company plans to introduce strategic investors through its holding subsidiary Zhejiang Medikai Optics & Semiconductors Co., Ltd. (hereinafter referred to as “Optical Semiconductor Company” or “Target Company”). The strategic investor Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (limited partnership) (hereinafter referred to as “Fuzhe Shaoxin”, the “investor” or “capital increase party”) plans to increase capital to the optical semiconductor company with RMB 200 million in cash according to a pre-investment valuation of 2.18 billion yuan. After the capital increase is completed, Fuzhe Shaoxin's shareholding ratio in the optical semiconductor company is 8.40%. The capital increase will be mainly used for the main business of optical semiconductor companies and other uses approved by Zhejiang Shaoxin. The price of this capital increase shall not be directly or indirectly transferred to Medicare or other entities or related parties actually controlled by it for any purpose.

The current capital increase and stock expansion of optical semiconductor companies and the introduction of strategic investors will help to enrich their financial strength, better meet the capital requirements for the development of the main business operation and development of optical semiconductor companies, gather superior resources from various parties to form a synergy effect, and further enhance the core competitiveness and sustainable development capabilities of optical semiconductor companies. After the capital increase was completed, Mediq is still the controlling shareholder of Optical Semiconductor Company, and Optical Semiconductor Company is still included in the scope of Medicare's consolidated statements.